Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve life, improve patient outcomes, reduce the cost of care, and take noninvasive monitoring to new sites and applications. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown to outperform other pulse oximetry technologies in over 100 independent and objective studies, which can be found at www.masimo.com/evidence/featured-studies/feature. Masimo SET® is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2025 Newsweek World’s Best Hospitals listing. Additional information about Masimo and its products may be found at www.masimo.com.
Unlock the market timeline & signal feed
17 signals in the last 90 days.
The order this company entered each market — oldest to newest
28 active postings
Government & Reimbursement Manager
Sign up to see the full signal feed
How Masimo's international expansion compares to its competitors
MasimoYouBars show relative size across the companies compared.
Columns5| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 MasimoYou | 7 | 2 | +29% | 16 | 31 |
Area Clinical Resource Manager
View postingIrvine, CA · 4d ago
Customer Service Representative
View postingIrvine, CA · last wk.
Manager, OEM Product Development
View postingIrvine, CA · last wk.
Study Finds That When Patients Decline, Respiratory Changes Often Come First
Active
Patient deterioration often begins with respiratory compromise
Active
Learn how early detection of respiratory changes can support patient safety
ActiveApple reintroduces blood oxygen measurement to certain smartwatch models via software update after US approval, amid ongoing legal dispute with Masimo.
US International Trade Commission ruled Apple's redesigned Watch Series 9 and Ultra 2 do not infringe Masimo's blood oxygen monitoring patents, rejecting import ban request.
Danaher reports 30% surge in bioprocessing orders and 10% earnings per share growth in Q1, but lowers respiratory product revenue forecast by $150 million while maintaining 3-6% organic growth outlook.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Masimo's business, markets, and growth signals.
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
© 2026 Pubrio. All rights reserved.
